Please login to the form below

Not currently logged in
Email:
Password:

Lixiana

This page shows the latest Lixiana news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Latest news

  • Daiichi Sankyo to shut down German antibody unit U3 Daiichi Sankyo to shut down German antibody unit U3

    Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for

  • Daiichi Sankyo cuts a swathe through US workforce Daiichi Sankyo cuts a swathe through US workforce

    The company is hoping that newer products such as novel oral anticoagulant (NOAC) Savaysa/Lixiana (edoxaban) will eventually fill the void left by Benicar, which is facing a challenging start as

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).

  • NICE recommends Daiichi Sankyo's Lixiana for DVT and PE NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

    NICE has backed Daiichi Sankyo's Lixiana (edoxaban) in final guidance as a treatment for adults with deep vein thrombosis and pulmonary embolism. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better

  • Daiichi’s new anticoagulant recommended by NICE Daiichi’s new anticoagulant recommended by NICE

    NICE is recommending Daiichi Sankyo's new blood thinner Lixiana as a treatment to help patients with a heart flutter who have an increased risk of stroke. ... NICE has already recommended Lixiana for the treatment of deep vein thrombosis and pulmonary

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics